OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 69. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	251
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047	229
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	191
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	169
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment	169
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	164
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	160
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	157
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	144
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	139
Commentary on oncolytic viruses: past, present, and future	129
Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	127
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	127
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwid	123
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	123
Is immunotherapy safe and effective in patients with VEXAS syndrome?	117
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	115
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	113
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas	111
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	111
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	108
T-cell tolerant fraction as a predictor of immune-related adverse events	107
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	105
Single-cell analysis reveals clonally expanded tumor-associated CD57 ⁺ CD8 T cells are enriched in the periphery of patients with metastatic urotheli	105
Biomarkers for response to TIL therapy: a comprehensive review	103

Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	102
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis	102
iRECIST and atypical patterns of response to immuno-oncology drugs	101
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	99
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	96
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells	95
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	95
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	93
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	91
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	89
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	88
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	88
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	87
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	87
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	86
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	86
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	86
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	85
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	85
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity	85
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	83
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	81
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	80
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	79
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	78
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	77
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	77
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	76
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade	76
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	75
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	75
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	75
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity	74
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8⁺ T cell cytotoxicity over BEMPEG+RT	74
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia	73
Targeting KDM4C enhances CD8⁺ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer	73
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study	72
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma	72
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species	71
Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL	71
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy	71
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer	71
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8⁺ T cell-dependent antitumor immunity and abscopal effect after local irradiation	70
Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer	69
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer	69
Modulating lipid metabolism improves tumor immunotherapy	69